title: Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Saylor
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Keating
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Freedland
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Smith
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000453:epidemiology*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D015994:Incidence; D008297:Male; D011471:Prostatic Neoplasms / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone